1. Risk Haplotypes Uniquely Associated with Radioiodine-Refractory Thyroid Cancer Patients of High African Ancestry
- Author
-
Brynn Hollingsworth, Jennifer A. Sipos, Luke K Genutis, Yi Seok Chang, Christopher J. Walker, Pamela Brock, Electron Kebebew, Patience Green, Fadi Nabhan, W. G. Li, Sandya Liyanarachchi, Gilbert J. Cote, Steven I. Sherman, Sissy M. Jhiang, Albert de la Chapelle, Shuai Xue, Zachary A. Hurst, Huiling He, and Eric Menq
- Subjects
Adult ,Male ,Proto-Oncogene Proteins B-raf ,Oncology ,medicine.medical_specialty ,Adolescent ,Endocrinology, Diabetes and Metabolism ,030209 endocrinology & metabolism ,Disease ,Polymorphism, Single Nucleotide ,Radiation Tolerance ,Risk Assessment ,Thyroglobulin ,White People ,Iodine Radioisotopes ,Ligases ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,Endocrinology ,Refractory ,Risk Factors ,hemic and lymphatic diseases ,Internal medicine ,Biomarkers, Tumor ,medicine ,Humans ,Genetic Predisposition to Disease ,Thyroid Neoplasms ,Thyroid cancer ,Germ-Line Mutation ,Aged ,African american ,BRCA1 Protein ,business.industry ,Incidence ,Haplotype ,Thyroid Cancer and Nodules ,Middle Aged ,medicine.disease ,United States ,Black or African American ,Phenotype ,Haplotypes ,030220 oncology & carcinogenesis ,Female ,Radiopharmaceuticals ,business - Abstract
Background: Thyroid cancer patients with radioiodine-refractory (RAI-R) disease, resulting from insufficient RAI delivery and/or RAI resistance, have increased mortality and limited treatment options. To date, studies have largely focused on tumor mutations associated with different stages of disease, which could provide prognostic value for RAI-R disease. It was hypothesized that germline variants contributing to intrinsic differences in iodine metabolism, tumor microenvironment, and/or immune surveillance are associated with RAI-R disease. Methods: Whole-genome genotyping data analysis was performed on 1145 Caucasian (CAU) patients, 244 of whom were RAI-R, and 55 African American (AA) patients, nine of whom were RAI-R. Germline-variant association studies were conducted using candidate genes involved in iodine metabolism or DNA-damage repair, as well as genome-wide association analysis. Initial data indicated several notable variants in a small number of patients (n = 7), who were later determined to be AA patients of >80% African ancestry (n = 37). This led to the study focusing on germline single nucleotide polymorphisms uniquely associated with RAI-R AA patients. Sanger sequencing was performed to validate risk alleles and identify the incidence of the common somatic mutations BRAF(V600E), NRAS(Q61R), and HRAS(Q61R) in AA patients whose primary tumor samples were available (28/55). Results: TG, BRCA1, and NSMCE2 haplotypes were identified as being uniquely associated with RAI-R AA patients of >80% African ancestry. All patients with the TG haplotype (n = 4) had a biochemical incomplete response to RAI therapy. Patients with the NSMCE2 haplotype (n = 4) were diagnosed at a young age (13, 17, 17, and 26 years old) with distant metastatic disease at initial diagnosis. The BRCA1 haplotype co-occurred in three out of four patients with the NSMCE2 haplotype. The incidence of BRAF(V600E) appears lower in papillary thyroid carcinomas from AA patients of >80% African ancestry (3/14; 21%) than in AA patients of
- Published
- 2019
- Full Text
- View/download PDF